Acetyl Tetrapeptide-11
/ Synthetic acetylated tetrapeptide; INCI 'Acetyl Tetrapeptide-11'; tenascin-X / dermal density cosmetic peptideALIAS · Syniorage (trade) · Acetyl Tetrapeptide-11 (INCI)
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4 cosmeceutical. INCI catalog peptide marketed under the Syniorage trade name (Sederma). Mechanism positioning centres on tenascin-X expression and dermal-density restoration; primary literature outside supplier white papers and INCI catalog material is essentially absent.
The supplier-stated mechanism is upregulation of tenascin-X (TN-X), an extracellular-matrix glycoprotein implicated in dermal collagen organisation and elasticity. The biological rationale draws on the dermal phenotype of TN-X-deficient connective tissue disorders, where loss-of-function presents with skin fragility and laxity. Whether topical application of a four-residue peptide engages this pathway in intact human skin to a clinically meaningful degree is not established in independent peer-reviewed literature.
None substantive. Supplier white papers and INCI documentation describe in-vitro and small panel observations; no PubMed-indexed primary literature for Acetyl Tetrapeptide-11 specifically is identifiable as of this writing.
No formal human safety database in the indexed literature. Topical cosmetic use is generally well tolerated per industry surveillance, but the absence of independent published characterisation is a real gap.
Regulatory status
- FDA status:
- Not FDA-approved
The published evidence base is effectively a supplier marketing artefact rather than a peer-reviewed pharmacology corpus. Vendor-formulation product positioning relies on the INCI catalog mechanism narrative; buyers cannot independently verify dermal-density claims against peer-reviewed clinical data.